2,4,6-trinitrobenzene sulfonic acid-induced chronic colitis with fibrosis and modulation of TGF-β1 signaling.

AIM To investigate whether targeting proteasome might reverse intestinal fibrosis in rats. METHODS Chronic colitis was induced in rats by repeated administration of increasing dose of 2,4,6-trinitrobenzene sulfonic acid (TNBS, 15, 30, 45, 60, 60, 60 mg) by rectal injection for 6 wk (from day 0 to day 35), while control rats received the vehicle. TNBS + bortezomib (BTZ) rats received intraperitoneal injections of BTZ twice weekly (from day 37 to day 44) at a dose of 25 mg/kg, whereas the control and TNBS groups received the same amount of the vehicle. Histologic scoring of inflammation and fibrosis was performed. Colonic production of transforming growth factor (TGF)-β was measured by ELISA. Colon fibrosis-related proteins such as phospho-p38, phospho-SMAD2/3, Akt and peroxisome proliferator activated receptor γ (PPARγ) were studied by western blot. Expression of the tight junction proteins, occludin and claudin-1, were assessed by Western blot. Colon proteasome activities (chymotrypsin-like and trypsin-like activities) were assessed. RESULTS TNBS-treated rats had a higher colon weight/length ratio compared to control rats (P < 0.01). Furthermore, fibrosis and inflammation scores were higher in TNBS-treated rats compared to control rats (P < 0.01 for both). Colonic production of TGF-β production tended to be higher in TNBS-treated rats (P < 0.06). Fibrosis-related proteins such as phospho-p38, phospho-SMAD2/3, and PPARγ were significantly higher in TNBS-treated rats compared to control rats (all P < 0.05). TNBS rats had a higher expression of Akt compared to control rats (P < 0.01). Tight junction proteins were modified by repeated TNBS challenge: colon occludin expression rose significantly (P < 0.01), whereas claudin-1 expression fell (P < 0.01). Bortezomib inhibition significantly decreased chymotrypsin-like activity (P < 0.05), but had no significant effect on trypsin-like activity (P > 0.05). In contrast, bortezomib had no effect on other studied parameters such as fibrosis score, TGF-β signaling, or tight junction expression (P > 0.05 for all). CONCLUSION Rats with TNBS-induced chronic colitis exhibited colon fibrosis associated with higher TGF-β signaling. Proteasome inhibition by bortezomib had no effect on fibrosis in our experimental conditions.

[1]  Ihor Batruch,et al.  Collective migration of cancer‐associated fibroblasts is enhanced by overexpression of tight junction‐associated proteins claudin‐11 and occludin , 2014, Molecular oncology.

[2]  S. Lecleire,et al.  Enteral glutamine infusion modulates ubiquitination of heat shock proteins, Grp-75 and Apg-2, in the human duodenal mucosa , 2014, Amino Acids.

[3]  S. Abdulnour-Nakhoul,et al.  Alterations in junctional proteins, inflammatory mediators and extracellular matrix molecules in eosinophilic esophagitis. , 2013, Clinical immunology.

[4]  B. Wiedenmann,et al.  Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[5]  C. Bole-Feysot,et al.  Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-κB in rats with TNBS-induced colitis. , 2013, The Journal of nutritional biochemistry.

[6]  P. Mulder,et al.  Magnetic resonance colonography in rats with TNBS‐induced colitis: A feasibility and validation study , 2012, Inflammatory bowel diseases.

[7]  A. Işık,et al.  Proteasome Inhibition Prevents Development of Experimental Dermal Fibrosis , 2012, Inflammation.

[8]  Y. Tada,et al.  Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice , 2012, PloS one.

[9]  A. Luke,et al.  Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: Impact of a “Top‐Down” approach to intestinal fibrosis in mice , 2012, Inflammatory bowel diseases.

[10]  T. Wight,et al.  The extracellular matrix: an active or passive player in fibrosis? , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[11]  J. Sznajder,et al.  Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β1 signalling , 2011, Thorax.

[12]  J. Rubin,et al.  Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn's disease. , 2011, Gastroenterology.

[13]  F. Guarner,et al.  Transforming growth factor‐beta type 1 receptor (ALK5) and Smad proteins mediate TIMP‐1 and collagen synthesis in experimental intestinal fibrosis , 2011, The Journal of pathology.

[14]  P. Déchelotte,et al.  An α-linolenic acid-rich formula reduces oxidative stress and inflammation by regulating NF-κB in rats with TNBS-induced colitis. , 2010, The Journal of nutrition.

[15]  H. Mollenkopf,et al.  Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis , 2010, Gut.

[16]  P. Déchelotte,et al.  Dietary modulation of peroxisome proliferator-activated receptor gamma , 2008, Gut.

[17]  E. Mizoguchi,et al.  Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. , 2007, World journal of gastroenterology.

[18]  J. Willis,et al.  A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. , 2003, Gastroenterology.

[19]  T. Macdonald.  A mouse model of intestinal fibrosis? , 2003, Gastroenterology.

[20]  A. Andoh,et al.  N-3 fatty acid-rich diet prevents early response of interleukin-6 elevation in trinitrobenzene sulfonic acid-induced enteritis. , 2003, International journal of molecular medicine.

[21]  M. Neurath,et al.  Local administration of antisense phosphorothiate olignucleotides to the p65 subunit of NF–κB abrogates established experimental colitis in mice , 1996, Nature Medicine.